EF Hutton Maintains Buy on Trevi Therapeutics, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Trevi Therapeutics (NASDAQ:TRVI) and maintained a price target of $21.
September 17, 2024 | 2:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Trevi Therapeutics and maintained a price target of $21, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $21 price target by EF Hutton suggests positive sentiment and confidence in Trevi Therapeutics' future performance. This could lead to increased investor interest and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100